Leaders' Update 
A message from Director Gordon Ginder
I am pleased to report that funding for Massey's Cancer Center Support Grant (CCSG) was recently renewed for this year.
This message continues with:
|
Novel gene target shows promise for bladder cancer detection and treatment
Preclinical experiments have provided evidence that melanoma differentiation associated gene-9/syntenin could be used as a therapeutic target to kill bladder cancer cells, help prevent metastasis and even be used to non-invasively diagnose the disease and monitor its progression.
|
 | |
Cancer Cell Signaling
member
|
New protein discovered with vast potential for treatment of cancer and other diseases
A novel protein called ceramide-1 phosphate transport protein (CPTP) was discovered that could potentially lead to the development of new drugs to treat a variety of cancers and other conditions involving inflammation and blood clotting.
|
Massey rated the top cancer center in Virginia
 For the second year in a row, Massey was rated the top provider in Virginia for high-performing cancer care in U.S. News & World Report's annual Best Hospitals list. Massey received the highest score in cancer care of the 20 Virginia cancer providers that made the list.
|
Member Showcase
 |
Cancer Molecular Genetics
member |
Andrei I. Ivanov, Ph.D., member of the Cancer Molecular Genetics program, focuses his research on epithelial cell biology and pathophysiology. He studies regulation of epithelial barriers and mechanisms that control remodeling of cell-cell and cell-matrix adhesions during inflammation and tumor progression. Ivanov is the editor in chief of a new international journal, Tissue Barriers.
|
Laura Siminoff awarded R01
Congratulations to Laura Siminoff, Ph.D., associate director for cancer prevention and control, who was awarded an R01 from NCI Cancer Control and Population Sciences.
The grant supports her study
investigating whether cancer communication between patients and their family caregivers is an important and independent factor in specific cancer care outcomes. The study focuses on adult patients with hematological malignancies because of the increased number of cases and unique social and psychological challenges.
|
Shared Resource Spotlight
|
Lipidomics Developing Shared Resource Core
The LDSRC is a key focal point for the development of a sustainable critical mass of expertise in lipid signaling and state-of-the-art analytical techniques.
The core features two tandem triple quadrupole/linear ion trap mass spectrometers, a high-end Applied Biosystems 4000 Q-TRAP and an Applied Biosystems 3200 Q-TRAP. These instruments have the necessary resolution and sensitivity for a broad range of qualitative and quantitative lipid and metabolite analyses required for exhaustive characterization of lipid signaling molecules and metabolic pathways.
Director:
Contact Information:
(804) 828-9762
|
